DoseSpot, backed by growth equity firm PSG, announced on June 7 it has acquired pVerify for an undisclosed price. According to data captured in the LevinPro HC database, this acquisition marks the 123rd eHealth transaction of 2023.
pVerify’s solution streamlines the front-end patient eligibility verification process, helps patients access necessary care and aims to reduce overall healthcare costs. The company was founded in 2006.
DoseSpot provides e-prescription software, enabling clinicians to write and transmit prescriptions to pharmacies electronically. The DoseSpot solution eases the administrative burden of the prescription life cycle by integrating with electronic medical records (EMRs)/electronic health records (EHRs) and other practice management software. Founded in 2009, DoseSpot serves more than 300 healthcare clients – reaching more than 200,000 healthcare professionals – from digital/telehealth providers and hospice pharmacies to dental services organizations and EMR/EHR and practice management software companies.
Ernst & Young served as financial advisor and Weil Gotshal & Manges LLP served as legal counsel to PSG and DoseSpot. Allied Advisers served as financial advisor and Stradling Yocca Carlson & Rauth served as legal counsel to pVerify.
This partnership furthers DoseSpot’s commitment to innovation, following its acquisition of ePrescribing platform TreatRx in March 2023 and a strategic investment in January 2022 led by PSG. Following the close of the transaction, both DoseSpot and pVerify will continue to operate independently and will work together to identify natural points of cross-collaboration and integration.
